Coronavirus disease 2019 vaccination is protective of clinical disease in solid organ transplant recipients
Open Access
- 24 February 2022
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 24 (2) , e13788
Abstract
Background: Clinical effectiveness of coronavirus disease 2019 (COVID‐19) vaccination in solid organ transplant recipients (SOTRs) is not well documented despite multiple studies demonstrating sub‐optimal immunogenicity.Methods: We reviewed medical records of eligible SOTRs at a single center to assess vaccination status and identify cases of symptomatic COVID‐19 from January 1 to August 12, 2021. We developed a Cox proportional hazards model using the date of vaccination and time since transplantation as a time‐varying covariate with age and gender as potential time‐invariant confounders. Survival curves were created using the parameters estimated from the Cox model. Results: Among 1904 SOTRs, 1362 were fully vaccinated (96% received mRNA vaccines) and 542 were either unvaccinated (n = 470) or partially vaccinated (n = 72). There were 115 cases of COVID‐19, of which 12 occurred in fully vaccinated individuals. Cox regression with the date of vaccination and time since transplantation as the time‐varying co‐variates showed that after baseline adjustment for age and sex, being fully vaccinated had a significantly lower hazard for COVID‐19, hazard ratio (HR) = 0.29 and 95% confidence interval ([CI] 0.09, 0.91).Conclusion: We found that 2‐dose mRNA COVID‐19 vaccination was protective of symptomatic COVID‐19 in vaccinated versus unvaccinated SOTRs.Tweet: COVID‐19 vaccination was associated with a significantly lower hazard for symptomatic COVID‐19 (HR 0.29; 95% CI 0.09, 0.91) among 1904 SOT recipients at a single center from January 1 to August 12, 2021.Keywords
Funding Information
- Cystic Fibrosis Foundation (ASLAM20A0‐I)
- National Institute of Allergy and Infectious Diseases (R3761154)
- Center for AIDS Research, University of California, San Diego (AI036214)
- National Center for Advancing Translational Sciences (UL1TR001442)
This publication has 10 references indexed in Scilit:
- Changing trends in mortality among solid organ transplant recipients hospitalized for COVID-19 during the course of the pandemicAmerican Journal of Transplantation, 2022
- Low mortality in SARS‐CoV‐2 infected heart transplant recipients at a single centerClinical Transplantation, 2021
- Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System WorkforceNew England Journal of Medicine, 2021
- Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant RecipientsNew England Journal of Medicine, 2021
- Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant — National Healthcare Safety Network, March 1–August 1, 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant RecipientsNew England Journal of Medicine, 2021
- Clinical effectiveness of COVID‐19 vaccination in solid organ transplant recipientsTransplant Infectious Disease, 2021
- Two Doses of SARS-CoV-2 Vaccines Reduce Risk of Death Due to COVID-19 in Solid Organ Transplant Recipients: Preliminary Outcomes From a UK Registry Linkage AnalysisTransplantation, 2021
- Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients With Coronavirus Disease 2019 (COVID-19)Clinical Infectious Diseases, 2021
- Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant RecipientsJAMA, 2021